Update to 01/26/21 COVI-MSC™ Press Release: Fourth Patient Also Released From Hospital Following Third Infusion of Stem Cells
January 31, 2021 17:28 ET
|
Sorrento Therapeutics, Inc.
Fourth patient, who spent more than two weeks in hospital and needed invasive mechanical ventilation, was treated with COVI-MSC starting Monday (January 25, 2021) and discharged last Friday (January...
Sorrento Announces Positive Preliminary Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients
January 26, 2021 19:09 ET
|
Sorrento Therapeutics, Inc.
First three patients discharged from Hospital ICU within 8 days from initial IV administration No infusion-related adverse events noted for any patient treated to date SAN DIEGO, Jan. 26, 2021 ...
Arch Biopartners Receives Government of Canada Funding to Support Phase II Therapeutic Trial of Metablok for COVID-19
December 15, 2020 12:52 ET
|
Arch Biopartners
Government of Canada contribution up to $6.7 MillionFunding from the department of Innovation, Science and Economic Development through the Strategic Innovation Fund and part of the Government of...
Equillium Receives FDA Clearance of COVID-19 IND for Phase 3 Trial
October 29, 2020 16:13 ET
|
Equillium
Equillium plans to initiate global Phase 3 COVID-19 trial – EQUINOX – during Q4 2020 FDA indicates study could support BLA filing LA JOLLA, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Equillium,...
Sorrento Adds Mesenchymal Stem Cell Program (MSC) That Has Been Cleared for a Phase 1 Trial by the FDA to the Pipeline of COVID-19 Focused Rescue Therapies
October 12, 2020 17:21 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that it has entered into an exclusive license agreement with Personalized Stem...
Equillium Announces Successful Completion of FDA Pre-IND Meeting Enabling Advancement of Itolizumab into a Potential Registration Study as a Treatment for Hospitalized COVID-19 Patients
September 15, 2020 08:07 ET
|
Equillium
Equillium anticipates filing a U.S. IND for Itolizumab for COVID-19 and initiating a global Phase 3 clinical study in Q4 2020 LA JOLLA, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc....
Trevena Announces Initiation of TRV027 Study in COVID-19 Patients in Collaboration With Imperial College London
August 24, 2020 07:00 ET
|
Trevena Inc.
-- TRV027 is a novel AT1 receptor selective agonist with the potential to treat acute lung damage / abnormal blood clotting associated with COVID-19 The Company expects to report topline data in Q1...
Arch Biopartners to Hold LSALT Peptide Webinar Today at 11am EST
August 18, 2020 08:16 ET
|
Arch Biopartners
TORONTO, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) will host a webinar today at 11:00am EST to present an overview of the...
Equillium Reports Second Quarter 2020 Financial Results and Recent Highlights
August 12, 2020 08:37 ET
|
Equillium
LA JOLLA, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Orion Biotechnology Receives Funding to Test OB-002 for Treatment of COVID-19
July 30, 2020 10:51 ET
|
Orion Biotechnology Canada Ltd.
Ottawa, Canada, July 30, 2020 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering small protein therapeutics, today...